Let’s Make A Deal: Lilly Won’t Up SGX Bid Of $64 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
$3 per share is Lilly’s best and final offer for the San Diego biotech.
You may also be interested in...
Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition
Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.
Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition
Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.
Lilly Buying SGX For $64M In Cash
2003 partnership turns into takeover for structural biology firm.